Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 49,270 shares, an increase of 78.9% from the November 30th total of 27,540 shares. Based on an average trading volume of 146,092 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.7% of the company’s shares are sold short. Approximately 2.7% of the company’s shares are sold short. Based on an average trading volume of 146,092 shares, the days-to-cover ratio is presently 0.3 days.

Bluejay Diagnostics Stock Down 0.9%

Shares of BJDX opened at $0.70 on Friday. The company has a market cap of $1.27 million, a P/E ratio of -0.01 and a beta of 0.61. Bluejay Diagnostics has a fifty-two week low of $0.65 and a fifty-two week high of $10.20. The firm’s 50 day moving average price is $1.47 and its 200 day moving average price is $1.59.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Friday, November 7th. The company reported ($1.01) EPS for the quarter.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BJDX shares. Wall Street Zen raised Bluejay Diagnostics to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.